pharma news today obesity drugs glp-1 september 2025 Yearender: Health | After splash in 2025, weight-loss poised to take off this year | Explained What's next for GLP-1 innovation:

Laxatives work by pulling water into the gut or causing the intestinal muscle to contract, according to Mayo Clinic

And while Melanotan boosts melanin, it doesnt offer complete UV protectionwearing sunscreen is still essential when spending time outdoors

Uytkownicy zgaszali zarwno pozytywne efekty, takie jak zwikszona pigmentacja skry i poprawa libido, jak i negatywne skutki uboczne, w tym nudnoci, zaczerwienienie twarzy oraz spontaniczne erekcje

2020;10(8):e01726

Mounjaro (tirzepatide) Disease area(s): Metabolic diseases Manufacturer(s): Eli Lilly and Company 2024 Sales (USD): $11.54 billion Why it sold so well: Eli Lillys dual GIP and GLP-1 receptor agonist for type 2 diabetes, Mounjaro, experienced exceptional growth in 2024, with global sales more than doubling to $11.54 billion